Cargando…
A simplified Bcl-2 network model reveals quantitative determinants of cell-to-cell variation in sensitivity to anti-mitotic chemotherapeutics
Anti-mitotic drugs constitute a major class of cytotoxic chemotherapeutics used in the clinic, killing cancer cells by inducing prolonged mitotic arrest that activates intrinsic apoptosis. Anti-mitotics-induced apoptosis is known to involve degradation of anti-apoptotic Bcl-2 proteins during mitotic...
Autores principales: | Kueh, Hao Yuan, Zhu, Yanting, Shi, Jue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095668/ https://www.ncbi.nlm.nih.gov/pubmed/27811996 http://dx.doi.org/10.1038/srep36585 |
Ejemplares similares
-
Inhibition of Bcl-xL sensitizes cells to mitotic blockers, but not mitotic drivers
por: Bennett, Ailsa, et al.
Publicado: (2016) -
Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells
por: Qi, Chen, et al.
Publicado: (2018) -
Critical role of anti-apoptotic Bcl-2 protein phosphorylation in mitotic death
por: Eichhorn, J M, et al.
Publicado: (2013) -
How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma
por: Morris, Treen Carson Michael, et al.
Publicado: (2021) -
BCL-W is a regulator of microtubule inhibitor-induced mitotic cell death
por: Huang, Shan, et al.
Publicado: (2016)